Lutetium-177 (Lu-177) is a radioisotope that plays a pivotal role in nuclear medicine and the radiopharmaceutical industry due to its favorable characteristics. It is widely used in targeted radionuclide therapy (TRT) and is an integral part of the growing theranostics field, which combines therapy and diagnostics in one platform. Discover how Eckert & Ziegler supports the development and use of Lu-177-based radiopharmaceuticals with precision and reliability.
Lutetium-177 (Lu-177) is a critical part of modern nuclear medicine. Its half-life of 6.64 days offers a great balance between effective treatment time and manageable radioactive decay. The emission profile of Lu-177 consists of medium-energy beta-minus particles (Emax: 498.3 keV) and low-energy gamma radiation (Eγmax: 208 keV). This makes the isotope very suitable for therapeutic applications, as it delivers localized energy with maximal tissue penetration of <3 mm, enabling it to destroy cancer cells while sparing healthy tissue in surrounding areas.
Lu-177-based radioligand therapy is already well established in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) binding to somatostatin receptors on tumor cells. It has also emerged as a modern routine treatment option for metastatic prostate cancer by targeting the Prostate-Specific Membrane Antigen (PSMA). Numerous other applications are being investigated to expand the use of Lutetium-177 to areas such as bone metastases, hematological malignancies and other solid tumors with overexpressed target receptors.
From isotope production to drug product preparation, we deliver innovative solutions to drive the future of Lu-177 based radiopharmaceuticals. Discover how Eckert & Ziegler supports the development of targeted radiopharmaceuticals with unmatched precision and reliability.
Theralugand® is Eckert & Ziegler’s non-carrier-added (n.c.a.) Lutetium-177, produced in compliance with GMP standards. Approved by the European Medicines Agency (EMA) and with a US DMF Type II in place, Theralugand® unlocks the radionuclides potential to support innovative cancer therapies. Whether it be in clinical routine, radiopharmaceutical development or large-scale commercial supply, Eckert & Ziegler is your partner for reliable radioisotope supply.
Accelerate the clinical and commercial development of your radiopharmaceuticals with Eckert & Ziegler’s fully equipped GMP-certified laboratories. Our facilities support every step of your journey—from clinical trial batch production to reliable global distribution. Partner with us for compliant, high-quality contract manufacturing solutions tailored to your specific needs.
Efficiently label radiopharmaceuticals with our Modular-Lab product family. Eckert & Ziegler offers a comprehensive portfolio of devices and consumables tailored to support the preparation of Lu-177-based therapies. Whether for clinical trials or commercial production, our solutions ensure reliability and scalability for your radiolabeling needs.
Trust Eckert & Ziegler’s quality control devices to maintain the safety, efficacy, and compliance of your Lu-177-based radiopharmaceuticals. Whether it be for thin-layer (TLC) or high performance liquid chromatography (HPLC), our instruments provide precision measurements and robust performance, ensuring confidence in every batch.
From advancing cancer therapies to enhancing clinical trial outcomes, Eckert & Ziegler’s Lutetium-177 solutions are making an impact worldwide. We are committed to empowering nuclear medicine worldwide through all stages. Whether you’re developing new radiopharmaceuticals, streamlining your clinical routine or scaling commercial production, we are your trusted partner for success.
